Literature DB >> 21270403

Septic shock is associated with receptor for advanced glycation end products ligation of LPS.

Yasuhiko Yamamoto1, Ai Harashima, Hidehito Saito, Koichi Tsuneyama, Seiichi Munesue, So Motoyoshi, Dong Han, Takuo Watanabe, Masahide Asano, Shin Takasawa, Hiroshi Okamoto, Satoshi Shimura, Tadahiro Karasawa, Hideto Yonekura, Hiroshi Yamamoto.   

Abstract

Septic shock is a severe systemic response to bacterial infection. Receptor for advanced glycation end products (RAGE) plays a role in immune reactions to recognize specific molecular patterns as pathogen recognition receptors. However, the interaction between LPS, the bioactive component of bacterial cell walls, and RAGE is unclear. In this study, we found direct LPS binding to RAGE by a surface plasmon resonance assay, a plate competition assay, and flow cytometry. LPS increased TNF-α secretion from peritoneal macrophages and an NF-κB promoter-driven luciferase activity through RAGE. Blood neutrophils and monocytes expressed RAGE, and TLR2 was counterregulated in RAGE(-/-) mice. After LPS injection, RAGE(+/+) mice showed a higher mortality, higher serum levels of IL-6, TNF-α, high mobility group box 1, and endothelin-1, and severe lung and liver pathologies compared with RAGE(-/-) mice without significant differences in plasma LPS level. Administration of soluble RAGE significantly reduced the LPS-induced cytokine release and tissue damage and improved the LPS-induced lethality even in RAGE(-/-) as well as RAGE(+/+) mice. The results thus suggest that RAGE can associate with LPS and that RAGE system can regulate inflammatory responses. Soluble RAGE would be a therapeutic tool for LPS-induced septic shock.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21270403     DOI: 10.4049/jimmunol.1002253

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  74 in total

Review 1.  The receptor for advanced glycation end products and acute lung injury/acute respiratory distress syndrome.

Authors:  Weidun Alan Guo; Paul R Knight; Krishnan Raghavendran
Journal:  Intensive Care Med       Date:  2012-07-10       Impact factor: 17.440

2.  Pulmonary receptor for advanced glycation end-products promotes asthma pathogenesis through IL-33 and accumulation of group 2 innate lymphoid cells.

Authors:  Elizabeth A Oczypok; Pavle S Milutinovic; John F Alcorn; Anupriya Khare; Lauren T Crum; Michelle L Manni; Michael W Epperly; Adriane M Pawluk; Anuradha Ray; Tim D Oury
Journal:  J Allergy Clin Immunol       Date:  2015-04-28       Impact factor: 10.793

3.  Is Elevated Levels of Serum Soluble Receptor for Advanced Glycation End Products Harmful in Cigarette Smokers?

Authors:  Kailash Prasad
Journal:  Int J Angiol       Date:  2016-03-10

Review 4.  Unlocking the biology of RAGE in diabetic microvascular complications.

Authors:  Michaele B Manigrasso; Judyta Juranek; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Trends Endocrinol Metab       Date:  2013-09-03       Impact factor: 12.015

5.  A Chemically Modified Curcumin (CMC 2.24) Inhibits Nuclear Factor κB Activation and Inflammatory Bone Loss in Murine Models of LPS-Induced Experimental Periodontitis and Diabetes-Associated Natural Periodontitis.

Authors:  Muna S Elburki; Carlos Rossa; Morgana R Guimarães-Stabili; Hsi-Ming Lee; Fabiana A Curylofo-Zotti; Francis Johnson; Lorne M Golub
Journal:  Inflammation       Date:  2017-08       Impact factor: 4.092

6.  The receptor for advanced glycation end products mediates lung endothelial activation by RBCs.

Authors:  Nilam S Mangalmurti; Jessica L Friedman; Liang-Chuan Wang; Donna Stolz; Geetha Muthukumaran; Don L Siegel; Ann Marie Schmidt; Janet S Lee; Steven M Albelda
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-12-28       Impact factor: 5.464

Review 7.  RAGE: a new frontier in chronic airways disease.

Authors:  Maria B Sukkar; Md Ashik Ullah; Wan Jun Gan; Peter A B Wark; Kian Fan Chung; J Margaret Hughes; Carol L Armour; Simon Phipps
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

8.  In vitro anticancer effects of a RAGE inhibitor discovered using a structure-based drug design system.

Authors:  Ali Hafez Ali Mohammed El-Far; Seiichi Munesue; Ai Harashima; Akira Sato; Mika Shindo; Shingo Nakajima; Mana Inada; Mariko Tanaka; Akihiko Takeuchi; Hiroyuki Tsuchiya; Hiroshi Yamamoto; Hazem M E Shaheen; Yasser S El-Sayed; Shuhei Kawano; Sei-Ichi Tanuma; Yasuhiko Yamamoto
Journal:  Oncol Lett       Date:  2018-01-29       Impact factor: 2.967

9.  Senescence-dependent impact of anti-RAGE antibody on endotoxemic liver failure.

Authors:  Angela Kuhla; Mandy Hauke; Kai Sempert; Brigitte Vollmar; Dietmar Zechner
Journal:  Age (Dordr)       Date:  2013-01-15

Review 10.  Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis.

Authors:  Sherman S Leung; Josephine M Forbes; Danielle J Borg
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.